Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z0XM
|
|||
| Former ID |
DIB002212
|
|||
| Drug Name |
CBL0137
|
|||
| Indication | Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Cleveland biolabs
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24N2O2
|
|||
| Canonical SMILES |
CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C
|
|||
| InChI |
1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3
|
|||
| InChIKey |
JKCSODVERGVDLT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1197996-80-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:138650
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Facilitates chromatin transcription complex (FACT) | Target Info | Modulator | [2] |
| WikiPathways | HIV Life Cycle | |||
| RNA Polymerase II Transcription | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01905228) A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.